KIT and neoplasm: Among the seven patients with a KIT-exon 11 mutation who progressed, five had non-gastric GISTs (located in the small bowel, rectum, or duodenum) with a median tumor size of 158 mm (range 53.0–250.0 mm) prior to the initiation of imatinib therapy.